|
Colorectal Carcinoma
|
0.500 |
CausalMutation
|
disease |
CLINVAR |
|
|
|
|
Colorectal Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Further, somatic loss of function mutations in PPARgamma have been found in primary colorectal carcinomas.
|
10851250 |
2000 |
|
Colorectal Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
These findings suggest that PPARgamma gene polymorphism may be implicated with the development of colorectal cancers, in which K-ras gene is not mutated.
|
11956653 |
2002 |
|
Colorectal Carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Each colorectal carcinoma cell line expressed PPARgamma.
|
12711249 |
2003 |
|
Colorectal Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
This is the first report that IL6, IL8, and PPARG genes are important in relation to inflammation-related risk of sporadic CRC.
|
12839942 |
2003 |
|
Colorectal Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Here, we found that 15-hydroxy-eicosatetraenoic acid (15S-HETE), an endogenous ligand for PPARgamma, was significantly decreased in the serum of patients with colorectal cancer.
|
14566836 |
2003 |
|
Colorectal Carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Human colorectal cancer cell lines SW480 and HCT116 both expressed functional PPARgamma.
|
12606626 |
2003 |
|
Colorectal Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
The ability to counteract PPARgamma suggests that gammaORF4 plays a role in the pathogenesis of colorectal cancers.
|
15857827 |
2005 |
|
Colorectal Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Interactions of peroxisome proliferator-activated receptor {gamma} and diet in etiology of colorectal cancer.
|
15894676 |
2005 |
|
Colorectal Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Peroxisome proliferator-activated receptor gamma (PPAR(gamma)) ligands inhibit cell growth of colorectal cancer cells in most experimental models, but no significant effect could be observed in patients with colorectal cancer.
|
15911106 |
2005 |
|
Colorectal Carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
PPARG, the gene encoding the gamma isoform of the peroxisome proliferator-activated receptor (PPARgamma), is highly expressed in normal human pancreatic islet cells, is located at 3p25, and has been reported to sustain loss-of-function mutations in human colorectal carcinomas.
|
15853832 |
2005 |
|
Colorectal Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Further research is needed to investigate functional implications of polymorphisms of the PPAR-gamma gene in CRC development.
|
16108832 |
2005 |
|
Colorectal Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
No evidence that polymorphisms in CYP2C8, CYP2C9, UGT1A6, PPARdelta and PPARgamma act as modifiers of the protective effect of regular NSAID use on the risk of colorectal carcinoma.
|
16141797 |
2005 |
|
Colorectal Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
In this study, we evaluated the association between colorectal cancer and specific tumor mutations and the Pro12Ala (P12A) PPARgamma polymorphism.
|
16489531 |
2006 |
|
Colorectal Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Meat, milk, saturated fatty acids, the Pro12Ala and C161T polymorphisms of the PPARgamma gene and colorectal cancer risk in Japanese.
|
16965392 |
2006 |
|
Colorectal Carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
RT-PCR and Western blot analysis showed that both human CRC cell lines expressed PPARgamma mRNA and protein.
|
16520894 |
2006 |
|
Colorectal Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
We studied the association of SNPs in the IL-6 (-174G>C), IL-8 (-251T>A), TNFalpha (-308G>A), ICAM-1 (R241G and K469E), and PPARgamma (Pro12Ala) genes and the risk of CRC.
|
16937502 |
2006 |
|
Colorectal Carcinoma
|
0.500 |
Biomarker
|
disease |
CTD_human |
In this study, we evaluated the association between colorectal cancer and specific tumor mutations and the Pro12Ala (P12A) PPARgamma polymorphism.
|
16489531 |
2006 |
|
Colorectal Carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
The purpose of this study was to evaluate whether EP(1-4) subtype, PPAR gamma receptor and COX-1/COX-2 expression in colorectal cancer are related to tumor-specific mortality.
|
17290397 |
2007 |
|
Colorectal Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
PPARgamma agonists have been shown to reduce the growth of colorectal carcinoma cells in culture and in xenograft models.
|
17390024 |
2007 |
|
Colorectal Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
PPARgamma inhibitors also reduced CRC cell migration and invasion in assays in vitro and reduced both the number and size of metastases in a HT-29/SCID xenograft metastatic model of CRC.
|
17096328 |
2007 |
|
Colorectal Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Although PPARgamma agonists may not by themselves be capable to induce clinical tumor regression, their combination with chemotherapy drugs or other targeted therapies is worth pursuing in the treatment of colorectal carcinoma.
|
17659359 |
2007 |
|
Colorectal Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
On the contrary, two other SNPs, PLA2G2A c.435+230C>T and PPARG c.1431C>T (p.His477His), were associated with a decrease in CRC risk.
|
18992148 |
2008 |
|
Colorectal Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Farnesol (FOH) and geranylgeraniol (GGOH) possess anti-tumor potential, while peroxisome proliferator-activated receptor gamma (PPARgamma) has exhibited modulating effects in colorectal cancers.
|
18608213 |
2008 |
|
Colorectal Carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Influence of tumor peroxisome proliferator-activated receptor gamma and delta expression on postoperative mortality of patients undergoing colorectal cancer surgery.
|
19283612 |
2009 |